Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis

BACKGROUND: Trastuzumab deruxtecan (T-DXd) has been shown to benefit progression-free survival and overall survival in patients with metastatic breast cancer (mBC) after progression on ≥1 human epidermal growth factor receptor 2 (HER2)-targeted therapies. However, interstitial lung disease (ILD) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Soares, L.R., Vilbert, M., Rosa, V.D.L., Oliveira, J.L., Deus, M.M., Freitas-Junior, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485391/
https://www.ncbi.nlm.nih.gov/pubmed/37481956
http://dx.doi.org/10.1016/j.esmoop.2023.101613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485391/
https://www.ncbi.nlm.nih.gov/pubmed/37481956
http://dx.doi.org/10.1016/j.esmoop.2023.101613

Ejemplares similares